McKesson names first ‘chief impact officer’

McKesson Corp. on Thursday appointed Dr. Kelvin A. Baggett to a newly created role focused on social issues: chief impact officer.

Baggett, who currently serves as managing director at a private equity firm, will start in the new role at the end of November. He’ll oversee the pharmaceutical and medical supply company’s strategies for community relations; diversity, equity and inclusion; sustainability and environmental, social and governance; and philanthropy through the McKesson Foundation.

The new appointment builds on a growing conversation taking place throughout the healthcare industry about how leadership can address social issues, such as structural racism.

Baggett’s “deeply informed perspective on inclusion, diversity, equity, sustainability and social impact will help us deliver on our company goals and help drive meaningful change for our employees, our customers, our investors and our communities,” said McKesson CEO Brian Tyler in a statement.

Baggett currently serves as managing director at Posterity Capital Group and as senior advisor at Pharos Capital Group, another private equity firm.

Baggett previously held titles as senior vice president, chief clinical officer and chief medical officer at Dallas-based Tenet Healthcare and chief operating officer and vice president of clinical strategies at Nashville, Tenn.-based HCA Healthcare. In 2016, he was named one of Modern Healthcare‘s Top 25 Minority Executives in Healthcare.

Irving, Texas-based McKesson earlier this month posted $60.8 billion in revenue for the second quarter of its fiscal 2021, up 5.5% year-over-year. The company’s U.S. pharmaceutical segment accounted for the majority of that revenue, making up $48.1 billion or 79% of the company’s total revenue for the quarter.


Tags: covid-19, pandemic

Thanks! You've already liked this